Divergent effects of copper and cisplatin on the endocytic trafficking of copper transporter-1.

Authors

Mainak Chakraborty, Swastika Dey, Sumanta Kar, Arnab Gupta

Published in

FEBS letters. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

Cisplatin (CDDP), a widely used chemotherapeutic agent, enters mammalian cells through high-affinity copper transporter CTR1. We found that copper preloading reduces CDDP cytotoxicity, supporting a shared uptake mechanism for copper and cisplatin. CDDP-induced CTR1 endocytosis requires both the amino-terminal His-Met motifs and the conserved 150MXXM154 pore-motif, similar to copper-mediated transport. Following internalization, CTR1 is routed through VPS35-positive endosomes and ultimately targeted to lysosomes. However, unlike copper, CDDP suppresses local recycling of CTR1 to plasma membrane and delays its lysosomal delivery. While copper promotes rapid lysosomal clearance of CTR1, CDDP results in prolonged intracellular trafficking. Additionally, CDDP enhances lysosomal size and cathepsin activity, indicating lysosomal activation. These findings reveal distinct mechanisms underlying CTR1-mediated cisplatin uptake and its impact on lysosomal physiology.

PMID:
42612009
Bibliographic data and abstract were imported from PubMed on 19 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.